Almirall partner MC2 on the verge of EU victory after ten years of hard work
The fact that MC2 therapeutics is close to its EU and US launch for the psoriasis treatment Wynzora is a significant milestone, says CEO Jesper Lange.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
On Tuesday, MC2 Therapeutics and its partner Almirall announced that they had completed the EU decentralized procedure for the psoriasis treatment Wynzora, which is the last step before individual the health authorities in individual European countries can start issuing marketing authorizations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Almirall starts the year with solid growth
For subscribers
Leo Pharma struggles with lawsuit in the US
For subscribers
